Suchergebnisse - "Markowski, Mark C"

PubPharm (7)

1

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

enthalten in: The Journal of clinical investigation | 2022

von Sena, L. | Kumar, R. | Sanin, D. | +22

2

A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE) : A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts

enthalten in: European urology | 2021

von Markowski, M. | Wang, H. | Sullivan, R. | +13

3

TRANSFORMER : A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Denmeade, S. | Wang, H. | Agarwal, N. | +25

4

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

enthalten in: The Prostate | 2020

von Markowski, M. | Shenderov, E. | Eisenberger, M. | +4

5

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

enthalten in: European urology | 2020

von Isaacsson Velho, P. | Fu, W. | Wang, H. | +11

CommentIn: Eur Urol. 2020 Jan;77(1):22-23. - PMID 31300236

6

Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide

enthalten in: The Prostate | 2016

von Markowski, M. | Frick, K. | Eshleman, J. | +2

7

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

enthalten in: Asian journal of andrology | 2015

von Markowski, M. | Pienta, K.

1
[1]